Profil
Die Universitätsklinik bietet eine umfassende Diagnostik und Therapie urologischer Erkrankungen, einschliesslich grosser Operationen an Blase, Prostata und Nieren, wie beispielsweise Zystektomie, Blasenersatz, Prostatektomie und (partielle) Nephrektomie. Darüber hinaus werden minimal-invasive Therapien der Prostata (TUR-P, HIFU, Thermotherapie, Laser-Enukleation), endoskopische, laparoskopische und robotergestützte Operationen an Nieren und Nebennieren sowie Operationen an der Harnröhre und komplexe rekonstruktive Verfahren angeboten.
Externe Partner
Prof. Marianna Rapsomaniki, UNIL/CHUV Lausanne; Prof. Alvaro Aytes Institut d’Investigació Biomèdica de Bellvitge, Program Against Cancer Therapeutic Resistance / Prostate Cancer Lab, Barcelona, Spanien; Prof. Theodore Alexandrov EMBL-Heidelberg, Structural and Computational Biology / Spatial Metabolomics Lab, Heidelberg, Deutschland; Prof. Rosalyn Adam, Urological Diseases Research Center, Boston Children’s Hospital, Boston, USA; Prof. Todd Purves, Duke University, Durham USA; Schweizerisches Institut für Bioinformatik, Theodor-Kocher Insitut, Universität Bern; ETH Zürich; Universitätsspital Balgrist, Zürich; ZHAW and EPFL; Prof. Ilaria Lucca, head of the department of Urology, CHUV, Lausanne; Prof. Joseph Liao Stanford University; Prof. Phil A. Beachy Stanford University; Prof. Marcus Drake, Department of Surgery & Cancer, Imperial College London; Prof. Sarah Waters University of Oxford; Prof. Dirk Lange, Stone Center, University of British Columbia; Swiss Paraplegic Center, Dr Andrew Gammie; Bristol Urological Institute
Research & Academic Partners
- Haute École Arc Ingénierie (HE-Arc) – project coordinator
- University of Bern
- ETH Zurich, specifically ETHZ’s NEXUS Personalized Health
- University of Applied Sciences and Arts Northwestern Switzerland (FHNW)
- CSEM (Centre Suisse d’Electronique et de Microtechnique)
- SSF SIPBB (Swiss Innovation Park Biel/Bienne)
Grants
3RCC (OC-2019-003); SNF Sinergia (202297); SNF SPARK (228930); SNF SPARK (212298); Innosuisse (101.951 IP-LS, 104.320 IP-LS); Wilhelm Sander Stiftung (2022.136.1); Schweizerische Krebsliga (KFS-5510-02-2022-R); EUREKA Eurostar (E!5995; E!6012) ISREC-TANDEM (CCP 10-3224-9); Novartis 23B099; SF Board Medical Faculty; Swiss National Science SISF; SNF R’Equip (229688); International Foundation for Research in Paraplegia (P195); UROPOT - Leenaards Foundation 2023; Swiss Paraplegic Foundation (BIPED), Bridge Discovery (40B2-0_226466), Bern MedTech Collaboration call 2024 and 2025 (PV-CATH-LUTDs, USAC-URO-DEVs), Swiss National Science Foundation SNSF (205320_204965);
Title: Unveiling Mediators of Heterogeneity in PDAC carrying TP53 and KRAS mutations
Institute: Swiss National Science Foundation External Lead Agency / Weave projects LS (Life Sciences)
01/11/2025-31/12/2029 CHF 2,500,000
Title: PROMETEX: Metabolically instructed personalized therapy selection for prostate cancer.
Institute: Swiss National Science Foundation – Sinergia
01/07/2021-30/06/2026 CHF 2’600’000
Title: Identification of a single cell proteomic spatial atlas of bladder cancer to characterize disease heterogeneity by imaging mass cytometry.
Institute: WihlemSander Foundation
30/09/2024-01/10/2025 CHF 170’000
Title: NIAC inhibitors for RCC
Institute: EUREKA Eurostar
01/11/2024-31/10/2026 CHF 900’000
DOPPL
AtG Therapeutics
Title: CK1 inhibitors for pancreatic adeno carcinoma
Institute: EUREKA Eurostar
01/11/2024-31/10/2027 CHF 1’000’000
CasInvent Pharma (Czech Republic)
eepLife (France)
AlveoliX (Switzerland)
Title: Single-centre’ phase 2’ open label’ two independent arms study assessing organoid-driven tumoral chemosensitivity in metastatic pancreatic cancer
nstitute: Hirslanden
01/11/2024-31/10/2026 CHF 500’000
Title: ORION
Institute: Innosuisse-FLAGSHIP
01/11/2025-31/10/2029 CHF 12’000’000
